NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models

•Combination therapy induced both adaptive and innate antitumor immunity.•Combination therapy significantly enhanced antitumor activity.•Combination therapy generated tumor antigen specific immune memory.•Bintrafusp alfa mediated the reduction of lung metastases.